[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Keimyung University Dongsan Medical Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":164},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,42,59,83,106,134],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100644311","the-effect-of-nsaid-on-serum-periostin-100644311",false,"NCT07662668","The Effect of NSAID on Serum Periostin","The Effect of Non-steroidal Antiinflammatory Drug on the Serum Periostin Level in Patients of Degenerative Disc Disease","Inclusion Criteria:\n\n* lumbar disc herniation\n* lumbar spinal canal stenosis\n* patients who have MRI\n\nExclusion Criteria:\n\n* allergic disease\n* allergic rhinitis\n* asthma\n* atopic dermatitis\n* chronic sinusitis\n* history of cancer\n* fracture within 6 months\n* severe osteoporosis\n* knee osteoarthritis\n* hip osteoarthritis\n* spinal surgery within 6 months\n* myocardiac infarction\n* heart failure\n* liver cirrhosis\n* chronic kidney disease\n* rheumatoid disease\n* systemic lupus erythematosus\n* ankylosing spondylitis\n* Crohn's disease\n* Ulcerative colitis\n* systemic steroid user\n* acute or chronic infection\n* BMI \\> 30\n* uncontrolled hypertension\n* uncontrolled diabetes\n* recent hisory vaccination",true,"ALL","20 Years","80 Years",{"count":21,"type":22},121,"ESTIMATED","OBSERVATIONAL","Low back pain (LBP) is one of the most prevalent musculoskeletal disorders worldwide and constitutes a major source of disability and socioeconomic burden. Intervertebral disc degeneration (IVDD) is recognized as one of the primary etiological contributors to LBP, and its prevalence increases substantially with age. The intervertebral disc (IVD) is a complex fibrocartilaginous structure composed of a central gelatinous nucleus pulposus (NP), a surrounding annulus fibrosus (AF), and superior and inferior cartilaginous endplates. The NP and AF cells synthesize a water-rich extracellular matrix (ECM) that confers the disc with its biomechanical properties, enabling load distribution and flexibility of the spinal column.\n\nUnder physiological conditions, ECM homeostasis within the IVD is tightly regulated; however, various intrinsic and extrinsic stimuli can disrupt this balance and initiate the degenerative cascade. IVDD has been attributed to a multitude of factors, including aging, obesity, genetic predisposition, mechanical overload, degeneration of the multifidus and psoas muscles, osteoporosis, oxidative stress, and chronic low-grade inflammation. Dysfunction of NP and AF cells, compounded by excessive endplate metabolic activity, leads to progressive endplate calcification, loss of disc hydration, structural failure of the AF, and ultimately irreversible IVDD. Among these contributing factors, elevated oxidative stress and increased secretion of pro-inflammatory cytokines-such as interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6)-have been shown to markedly accelerate the progression of IVDD by promoting ECM catabolism and suppressing anabolic repair processes.\n\nPeriostin (gene symbol: POSTN) is a matricellular ECM protein originally identified in the periosteum and periodontal ligament. It belongs to the fasciclin superfamily and plays a critical role in ECM assembly, tissue remodeling, and cell-matrix interactions. Periostin has been identified as a key mediator of mechanical stress responses, inflammatory signaling, and aging-related tissue changes, and is increasingly recognized as an important contributor to musculoskeletal pathology. Within the IVD, periostin binds to structural ECM molecules-including fibronectin, tenascin-C, and collagens-and participates in disc maintenance and repair. Conversely, dysregulated periostin expression promotes excessive ECM turnover and accelerates IVD degeneration through both mechanosensory and pro-inflammatory pathways. Importantly, serum periostin levels have been reported to be significantly elevated in patients with severe IVDD, and a recent clinical study demonstrated a strong positive correlation between serum periostin concentration and the Pfirrmann grading system, the most widely used MRI-based classification of disc degeneration severity.\n\nNonsteroidal anti-inflammatory drugs (NSAIDs) are among the most commonly prescribed pharmacological treatments for LBP, recommended in current clinical guidelines as first-line analgesic therapy. NSAIDs exert their primary effects through inhibition of cyclooxygenase (COX) enzymes, thereby suppressing prostaglandin synthesis and attenuating the inflammatory cascade. Beyond analgesia, NSAIDs may modulate the systemic inflammatory milieu in patients with IVDD by reducing circulating pro-inflammatory cytokine levels. Periostin expression is known to be upregulated by inflammatory mediators, including IL-4, IL-13, and TNF-α, and is closely linked to the overall inflammatory burden. It is therefore plausible that NSAID use may indirectly attenuate serum periostin elevation in patients with IVDD-related LBP; however, direct evidence for this hypothesis is currently lacking.\n\nTo date, no study has systematically compared serum periostin and inflammatory cytokine concentrations among patients with IVDD-related LBP who are using NSAIDs, those who are not using NSAIDs, and healthy controls without LBP. Elucidating these differences would not only advance our understanding of the role of systemic inflammation and ECM remodeling in IVDD pathophysiology, but would also help clarify whether NSAID use influences the biomarker profile of affected patients-with important implications for patient stratification and biomarker-guided management.",[26],"Intervertebral Disc Disease",[28],"intervertebral disc disease","RECRUITING","2026-06-24",{"date":32,"type":33},"2026-06-29","ACTUAL",{"date":35,"type":33},"2026-06-22",{"date":37,"type":22},"2028-05-30",{"name":39,"class":40},"Keimyung University Dongsan Medical Center","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":49,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":53,"startDateStruct":54,"completionDateStruct":55,"leadSponsor":57,"locationsCount":58},"100644205","relationship-of-periostin-and-odi-eq-5d-100644205","NCT07664904","Relationship of Periostin and ODI, EQ-5D","Study of Correlation Between Serum Periostin Levels and Oswestry Disability Index and EQ-5D","Inclusion Criteria:\n\n* lumbar disc herniation\n* lumbar spinal canal stenosis\n* patients who have MRI\n* patients who can fill in the ODI and EQ5D without other's help\n\nExclusion Criteria:\n\n* allergic disease\n* allergic rhinitis\n* asthma\n* atopic dermatitis\n* chronic sinusitis\n* history of cancer\n* fracture within 6 months\n* severe osteoporosis\n* knee osteoarthritis\n* hip osteoarthrtis\n* spinal surgery within 6 months\n* myocardiac infarction\n* heart failure\n* liver cirrhosis\n* chronic kidney disease\n* rhematoid disease\n* systemic lupus erythematosus\n* ankylosing spondylitis\n* Crohn's disease\n* Ulcerative colitis\n* systemic steroid user\n* acute or chronic infection\n* BMI \\> 30\n* uncontrolled hypertension\n* uncontrolled diabetes\n* recent history of vaccination",{"count":50,"type":22},38,"The intervertebral disc degeneration (IVDD) is a widely recognized musculoskeletal disorder that impose a substantial socioeconomic burden and respresents one of the most important causes of low back pain. IVDD can result from a variety of factors, including aging, obesity, genetic predispositioin, degeneration of of the multifidus and psoas muscles, osteoporosis, inflammation, and oxidative stress.\n\nThe IVD consists of a central gelatinous nucleus pulposus (NP), an outer annulus fibrosus (AF), and superior and inferior cartilaginous endplates. The NP and AF produce a water-rich extracellular matrix (ECM), which is essential for normal trunk function.\n\nDysfunction of the NP and AF, together with excessive metabolic activity of the enplates triggered by various intrinsic and extrinsic stimuli, leads to endplate degeneration and calcification, and ultimately to IVDD. In addition to aging and mechanical overload, increased oxidative stress and pro-inflammatrory cytokine secretion further accelerate the progression of IVDD.\n\nPeriostin is an ECM protein which is associated with mechanical stress, inflammation, and aging, and is known to be closely involved in the development and progression of IVDD. Periostin binds to ECM molecule within the IVD and participates in its maintenance and repair; however, excessive ECM turn over drives IVD degeneration and its progression. Periostin influences IVD degeneration through mechanical stress and inflammatory pathways, and serum periostin levels are elevated in patients with severe IVD degeneration. A recent study demonstrated strong corrrelation between serum periostin concentration and the Pfirmann grading system.\n\nThe Oswestry disability index is a validated scale that measures functional disability in patients with spinal pain, and the EQ-5D is a breif questionnaire used to assess health related quality of life. Because serum periostin levels reflect the severity of IVDD, periostin may also influence patient's functional disability and quality of life. However, whether serum periostin concentration correlates with functional disability and quality of life has not yet been studied.",[26],{"date":32,"type":33},{"date":35,"type":33},{"date":56,"type":22},"2027-02-27",{"name":39,"class":40},2,{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":11,"sex":17,"minAge":67,"maxAge":4,"enrollmentInfo":68,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":70,"conditions":71,"keywords":73,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":41},"100640140","feasibility-and-effectiveness-of-a-ring-type-blood-pressure-device-cart-bp-compared-with-24-hour-ambulatory-blood-pressure-monitoring-in-hfref-100640140","NCT07626879","Feasibility and Effectiveness of a Ring-Type Blood Pressure Device (CART-BP) Compared With 24-Hour Ambulatory Blood Pressure Monitoring in HFrEF","Feasibility and Effectiveness of a RING-type Blood Pressure Measurement Device (CART-BP) Compared With 24-Hour Ambulatory Blood Pressure Monitoring Device in Patients With Heart Failure With Reduced Ejection Fraction (RING-HFrEF)","RING-HFrEF","Inclusion Criteria:\n\n1. Age ≥ 19 years (male or female)\n2. Diagnosed with heart failure and currently under treatment\n3. Left ventricular ejection fraction (LVEF) ≤ 40% confirmed by echocardiography performed within 1 year prior to enrollment\n4. Able to undergo both 24-hour ambulatory blood pressure monitoring and ring-type blood pressure measurement\n5. Voluntarily provided written informed consent to participate in this clinical study\n\nExclusion Criteria:\n\n1. Office blood pressure: SBP \\\u003C 90 mmHg, or DBP \\\u003C 50 mmHg, or SBP \\> 180 mmHg, or DBP \\> 100 mmHg\n2. Unable to perform 24-hour ambulatory blood pressure monitoring\n3. Unable to wear or use the ring-type blood pressure device\n4. Variability in three consecutive resting cuff blood pressure measurements ≥ 20 mmHg (SBP) or ≥ 10 mmHg (DBP)\n5. Insufficient valid ABPM readings: \\\u003C 25 daytime or \\\u003C 12 nighttime measurements per ESH criteria; or \\\u003C 25 daytime or \\\u003C 12 nighttime valid readings from the ring-type device\n6. Pregnant, suspected pregnancy, or breastfeeding\n7. Judged by the investigator to be legally or mentally unfit to participate in the clinical study","19 Years",{"count":69,"type":22},100,"This study aims to evaluate the feasibility and diagnostic accuracy of the CART-BP ring-type wearable blood pressure monitoring device in comparison with 24-hour ambulatory blood pressure monitoring (ABPM) in patients with heart failure with reduced ejection fraction (HFrEF, LVEF ≤ 40%). As a multi-center, prospective, exploratory study, 100 patients will be enrolled at two tertiary hospitals in South Korea. The agreement between the two devices in 24-hour mean, daytime, and nighttime blood pressure measurements will be assessed per ISO 81060-2:2018 criteria.",[72],"Heart Failure With Reduced Ejection Fraction; Hypertension",[74],"HFrEF, ambulatory blood pressure monitoring, ABPM, wearable device, ring-type blood pressure, photoplethysmography, PPG, blood pressure validation","2026-05-29",{"date":77,"type":33},"2026-06-04",{"date":79,"type":33},"2025-10-23",{"date":81,"type":22},"2026-10-22",{"name":39,"class":40},{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":90,"targetDuration":4,"studyType":92,"phases":93,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":41},"100552347","comparison-of-pain-relief-and-peripheral-perfusion-index-100552347","NCT06471907","Comparison of Pain Relief and Peripheral Perfusion Index","Comparison of Pain Relief and Peripheral Perfusion Index Using Different Volume of Erector Spinae Plane Block","Inclusion Criteria:\n\n* lumbar disc herniation\n* lumbar foraminal stenosis\n* lumbar central stenosis\n* lumbar spondylolisthesis\n* numerical rating scale \\> 4\n* back pain functional scale \\\u003C 45\n* duration of pain \\> 1 mon\n* patients who can fully understand all items described in back pain functional scale\n\nExclusion Criteria:\n\n* Allergy to local anesthetics or contrast medium\n* Pregnancy\n* Spine deformity\n* Prior history of lumbar spine surgery\n* No previous lumbar MRI or CT\n* Patients with coagulation abnormality",{"count":91,"type":22},64,"INTERVENTIONAL",[94],"NA","The primary endpoint of this study is to compare the pain relief and peripheral perfusion index using different volume of local anesthetics in erector spinae plane block.",[97],"Erector Spinea Plane Block","2024-07-02",{"date":100,"type":33},"2024-07-05",{"date":102,"type":33},"2024-06-13",{"date":104,"type":22},"2025-04-30",{"name":39,"class":40},{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":17,"minAge":67,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":92,"phases":116,"briefSummary":117,"conditions":118,"keywords":120,"overallStatus":125,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":4},"100493454","simple-crossover-versus-side-branch-opening-in-patients-with-non-left-main-bifurcation-lesion-100493454","NCT05705362","Simple Crossover Versus Side Branch Opening in Patients With Non-Left Main Bifurcation Lesion","Randomized Controlled Trial of Simple CROSSsover Versus Side Branch Opening on Clinical Outcomes in Patients With Non-Left Main BIfurcation LeSion (CROSS-COBIS)","CROSS-COBIS","Inclusion Criteria:\n\n* (1) Subject must be at least 19 years of age\n* (2) Patients with non-left main bifurcation lesion (SB diameter ≥2.3 mm)\n* (3) Target lesions amenable for 1-stenting with provisional SB approach by operators' decision\n* (4) Angiographically compromised SB (visual SB stenosis ≥50%) after provisional MV stenting\n\nExclusion Criteria:\n\n* (1) Target lesions requiring elective 2-stenting technique by operators' decision (Observation Group 1)\\*\n* (2) Patients who inevitably require SB intervention after MV stenting, as follows. (Observation Group 2)\\*\n\n  1. Reduced SB TIMI flow (≤2) after MV stenting\n  2. SB dissection after MV stenting (≥ Type C)\n* (3) Patients without SB compromise after MV stenting (visually SB stenosis \\\u003C50%) (Observation Group 3)\\*\n* (4) Cardiogenic shock (Killip class IV) at presentation\n* (5) Patients with significant valvular heart disease or severe left ventricular systolic dysfunction (ejection fraction \\\u003C35%)\n* (6) Pregnancy or breast feeding\n* (7) Non-cardiac co-morbid conditions are present with life expectancy \\\u003C1 year or that may result in protocol non-compliance (per site investigator's medical judgment)\n* (8) Unwillingness or inability to comply with the procedures described in this protocol",{"count":115,"type":22},1000,[94],"Hypothesis:\n\nSimple crossover strategy would be non-inferior to SB opening strategy in the risk of target lesion failure (TLF) in patients with angiographically compromised SB (visually SB stenosis ≥50%) after provisional MV stenting for non-left main bifurcation lesion.\n\nA total of 1000 patients (500 per each group) with the angiographically compromised SB (visually SB stenosis ≥50%) after provisional MV stenting for non-left main bifurcation lesion will be enrolled. Patients will be randomized to either the simple crossover strategy group or SB opening strategy group at the time of enrollment with 1:1 ratio. Stratified randomization according to participating center, clinical presentation (acute coronary syndrome or stable ischemic heart disease), and type of bifurcation lesions (true or non-true) will be performed.",[119],"Coronary Artery Disease",[121,122,123,124],"Percutaneous coronary intervention","Bifurcation","Treatment strategy","Side branch","NOT_YET_RECRUITING","2023-01-26",{"date":128,"type":33},"2023-01-30",{"date":130,"type":22},"2023-03-01",{"date":132,"type":22},"2029-12-31",{"name":39,"class":40},{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":16,"sex":17,"minAge":67,"maxAge":142,"enrollmentInfo":143,"targetDuration":4,"studyType":92,"phases":145,"briefSummary":147,"conditions":148,"keywords":151,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":58},"100274987","phase-2-allogeneic-stem-cell-transplantation-in-relapsedrefractory-t--nkt-cell-lymphomas-100274987","NCT02859402","Allogeneic Stem Cell Transplantation in Relapsed\u002FRefractory T-, NK\u002FT-cell Lymphomas","Allogeneic Stem Cell Transplantation With 3-days Busulfan Plus Fludarabine as Conditioning in Patients With Relapsed or Refractory T-, NK\u002FT-cell Lymphomas","RRTCLAlloSCT","Inclusion Criteria:\n\n1. Age 19 - 65\n2. Histologically confirmed T or NK cell lymphomas :\n\n   * anaplastic large cell lymphoma\n   * angioimmunoblastic T-cell lymphoma,\n   * peripheral T-cell lymphoma, NOS\n   * NK\u002FT-cell lymphoma\n3. Relapsed after or refractory to one or more of previous chemotherapy including frontline autologous HSCT.\n4. At least one measured lesion using conventional CT or PET CT at the time of relapse after or refractory to one or more of previous chemotherapy and before salvage chemotherapy\n5. Complete or Partial response after short cycles of salvage chemotherapy\n6. Patients who have HLA full-match (8\u002F8 in HLA-A, B, C, DR by DNA high-resolution technique) or one-locus mismatch (7\u002F8) sibling, or unrelated bone marrow or peripheral blood or cord blood stem cell donors\n7. ECOG performance status ≤ 2\n8. Charlson Comorbidity Index (CCI) before HSCT ≤ 3\n9. Adequate renal function : serum creatinine level \\\u003C 2.0 mg\u002FdL\n10. Adequate liver function :\n\n    * Transaminase (AST\u002FALT) \\\u003C 3 X upper normal value (or \\\u003C 5 x ULN in the presence of lymphoma involvement of the liver)\n    * Total bilirubin \\\u003C 2 X upper normal value (or \\\u003C 5 x ULN in the presence of NK\u002FT involvement of the liver)\n11. Cardiac ejection fraction ≥ 50 % as measured by MUGA or 2D ECHO without clinically significant abnormality\n12. No clinically significant infection\n13. No clinically significant bleeding symptoms or sign\n14. Patients who decided to participate in this study and signed for a written consent\n\nExclusion Criteria:\n\n1. Adult T cell leukemia\u002Flymphoma, Lymphoblastic lymphoma, Primary cutaneous CD30+ T cell disorders Mycosis fungoides, Sezary SD\n2. Patients who have previously performed Allo-HSCT\n3. T cell lymphoma with primary central nervous system (CNS) Involvement.\n\n   \\*\\* However, patients who have only had prophylactic intrathecal or intravenous chemotherapy against CNS disease are eligible.\n4. Patients with a known history of HIV seropositivity or HCV (+).\n\n   \\*\\* Patients with HBV are eligible. However, primary prophylaxis using antiviral agents is recommended for HBV carrier or prevent HBV reactivation during whole treatment period.\n5. Any other malignancies within the past 5 years\n\n   \\*\\* Except curatively treated non-melanoma skin cancer or in situ carcinoma of cervix uteri\n6. Ejection fraction \\\u003C 50% by a echocardiography\n7. FEV1 \\\u003C60% or DLCO \\\u003C60% by a pulmonary function test\n8. ECOG performance status 3 or 4\n9. Combined serious medical problem or disease\n\n   * Serious or unstable heart disease although proper treatment\n   * Myocardial infarction in recent 3 months\n   * Underlying serious neurologic or psychiatric disease including dementia or seizure\n   * Active uncontrolled infection including hepatitis B and C\n   * Serious other medical problems observed by the doctors in charge of the patient\n10. Pregnant or lactating women, women of childbearing potential not employing adequate contraception","65 Years",{"count":144,"type":22},34,[146],"PHASE2","Relapsed and refractory T-cell lymphomas have been reported to have dismal outcomes. The role of allogeneic stem cell transplantation have been demonstrated in these patients. This clinical trial is studying the efficacy and safety of busulfan plus fludarabine as conditioning therapy followed by allogeneic stem cell transplantation (Allo-SCT) in T- and NK\u002FT-cell lymphoma patients who have relapsed or are refractory to previous chemotherapies including autologous transplantation.",[149,150],"T-cell Non-Hodgkin Lymphoma","Lymphoma, Extranodal NK-T-Cell",[149,152,153,154,155],"NK\u002FT-cell Non-Hodgkin Lymphoma","Relapsed, refractory","Conditioning","Allogeneic stem cell transplantation","2022-08-17",{"date":158,"type":33},"2022-08-18",{"date":160,"type":33},"2016-12",{"date":162,"type":22},"2027-12",{"name":39,"class":40},""]